Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

Annals of Oncology

Volumn 29, Issue 5, 2018, Pages 1108-1119

  Siena, Salvatore ^a,b   Sartore Bianchi, A ^a,b   Marsoni, S ^a,b,c   Hurwitz, H I ^d,f   McCall, S J ^d   Penault Llorca, F ^e   Srock, S ^f   Bardelli, A ^g,h   Trusolino, L ^g,h  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d DUKE CANCER INSTITUTE   (United States)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

Author keywords

Biomarker; Colorectal cancer; HER2; Targeted therapies

Indexed keywords

CAPECITABINE; CETUXIMAB; DS 8201; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAPATINIB; OXALIPLATIN; PANITUMUMAB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB DERUXTECAN; TRASTUZUMAB EMTANSINE; TUMOR MARKER; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESEARCH; COLORECTAL CANCER; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IN SITU HYBRIDIZATION; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; ONCOGENE NEU; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BIOPSY; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETIC SCREENING; GENETICS; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROGNOSIS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BIOPSY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GENE AMPLIFICATION; GENETIC TESTING; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PRECISION MEDICINE; PROGNOSIS; PROGRESSION-FREE SURVIVAL; RECEPTOR, ERBB-2;

EID: 85047605754     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy100     Document Type: Review

References (75)

1. Bertotti A, Papp E, Jones S et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015; 526(7572): 263-267
2. Sartore-Bianchi A, Loupakis F, Argilés G et al. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Ann Oncol 2016; 27(8): 1456-1466
3. Siravegna G, Marsoni S, Siena S et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017; 14(9): 531-548
4. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1(6): 508-523
5. The Cancer Genome Atlas Network (TCGAN). Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337
6. Sartore-Bianchi A, Trusolino L, Martino C et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/ 13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17(6): 738-746
7. Hurwitz H, Raghav KPS, Burris HA et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. J Clin Oncol 2017; 35: (suppl 4S; abstr 676)
8. Hainsworth JD, Meric-Bernstam F, Swanton C et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018; 36(6): 536-542
9. Laurent-Puig P, Balogoun R, Cayre A et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann Oncol 2016; 27: (suppl 6; abstr 459O)
10. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5(5): 341-354
11. Tzahar E, Waterman H, Chen X et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16(10): 5276-5287
12. Rakha EA, Pinder SE, Bartlett JM et al. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol 2015; 68(2): 93-99
13. Rüschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25(5): 637-650
14. Kim EK, Kim KA, Lee CY et al. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS One 2017; 12(2): e0171280
15. Ni S, Peng J, Huang D et al. HER2 overexpression and amplification in patients with colorectal cancer: a large-scale retrospective study in Chinese population. J Clin Oncol 2017; 35: (suppl; abstr e15099)
16. Richman SD, Southward K, Chambers P et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 2016; 238(4): 562-570
17. Valtorta E, Martino C, Sartore-Bianchi A et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015; 28(11): 1481-1491
18. Ingold Heppner B, Behrens HM, Balschun K et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014; 111(10): 1977-1984
19. Song Z, Deng Y, Zhuang K et al. Immunohistochemical results of HER2/ neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. Int J Clin Exp Pathol 2014; 7(7): 4454-4460
20. Conradi LC, Styczen H, Sprenger T et al. Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol 2013; 37(4): 522-531
21. Kruszewski WJ, Rzepko R, Ciesielski M et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers 2010; 29(5): 207-212
22. Kountourakis P, Pavlakis K, Psyrri A et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J 2006; 12(3): 229-236
23. Schuell B, Gruenberger T, Scheithauer W et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006; 6: 123
24. Essapen S, Thomas H, Green M et al. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 2004; 24(2): 241-248
25. McKay JA, Loane JF, Ross VG et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002; 86(4): 568-573
26. Rossi HA, Liu Q, Banner B et al. The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer J 2002; 8(3): 268-275
27. Osako T, Miyahara M, Uchino S et al. Immunohistochemical study of cerbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55(6): 548-555
28. Kapitanović S, Radosević S, Kapitanović M et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112(4): 1103-1113
29. Ross JS, Ali SM, Elvin JA et al. Targeted therapy for HER2 driven colorectal cancer. J Clin Oncol 2017; 35: (suppl 15; abstr 3583)
30. Shimada Y, Yagi R, Kameyama H et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Hum Pathol 2017; 66: 1-9
31. Gong J, Cho M, Sy M et al. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget 2017; 8(26): 42198-42213
32. Schrock AB, Young L, Klempner SJ et al. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced cancers of the GI tract and anus. J Clin Oncol 2017; 35: (suppl 4S; abstr 618)
33. Takegawa N, Yonesaka K, Sakai K et al. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. Oncotarget 2016; 7(3): 3453-3460
34. Edenfield WJ, Chung KY, Gatalica Z et al. Molecular profiling of HER2-positive colorectal cancer for identification of multiple potential drug targets. J Clin Oncol 2014; 32: (suppl 15; abstr e14508)
35. Weinberg BA, Poorman K, Arguello D et al. Impact of patient age on molecular alterations in left-sided colorectal tumors. J Clin Oncol 2017; 35: (suppl 15; abstr 3592)
36. Marshall J, Lenz H-J, Xiu J et al. Molecular variances between rectal and leftsided colon cancers. J Clin Oncol 2017; 35: (suppl 4S; abstr 522)
37. Siena S, Sartore-Bianchi A, Trusolino L et al. Final results of the HERACLES trial in HER2 amplified colorectal cancer. Anti-HER2 treatment in HER2+ mCRC. Oral presentation at the AACR Annual Meeting 2017, Washington, DC. Abstract CT005
38. Raghav KPS, Overman MJ, Yu R et al. HER2 amplification as a negative predictor biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 2016; 34: (suppl 15; abstr 3517)
39. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J clin Oncol 2013; 31(31): 3997-4013
40. Bartley AN, Washington MK, Colasacco C et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017; 35(4): 446-464
41. Seo AN, Kwak Y, Kim DW et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 2014; 9(5): e98528
42. Witzel I, Loibl S, von Minckwitz G et al. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 2010; 123(2): 437-445
43. Gevensleben H, Garcia-Murillas I, Graeser MK et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013; 19(12): 3276-3284
44. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann InternMed 1990; 113(10): 779-788
45. Mik M, Berut M, Dziki L et al. Right-and left-sided colon cancer-clinical and pathological differences of the disease entity in one organ. Arch Med Sci 2017; 13(1): 157-162
46. Arnold D, Lueza B, Douillard JY et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann Oncol 2017; 28(8): 1713-1729
47. Petrelli F, Tomasello G, Borgonovo K et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and metaanalysis. JAMA Oncol 2016 [Epub ahead of print], doi: 10.1001/jamaoncol.2016.4227
48. Holch JW, Ricard I, Stintzing S et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70: 87-98
49. Missiaglia E, Jacobs B, D'Ario G et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25(10): 1995-2001
50. Nam SK, Yun S, Koh J et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS One 2016; 11(3): e0151865
51. Sclafani F, Roy A, Cunningham D et al. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Ann Oncol 2013; 24(12): 3123-3128
52. Sun S-J, Lin Q, Sun Q et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J Can Res Ther 2016; 12(1): 323-333
53. Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med 2014; 92(7): 709-722
54. Siena S, Sartore-Bianchi A, Garcia-Carbonero R et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol 2018; 29(1): 119-126
55. Sepulveda AR, Hamilton SR, Allegra CJ et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Clin Oncol 2017; 35(13): 1453-1486
56. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27(8): 1386-1422
57. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer v2.2017. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (5 October 2017, date last accessed)
58. Yonesaka K, Zejnullahu K, Okamoto I et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3(99): 99ra86
59. Martin V, Landi L, Molinari F et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013; 108(3): 668-675
60. Ramanathan RK, Hwang JJ, Zamboni WC et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004; 22(6): 858-865
61. Clark JW, Niedzwiecki D, Hollis D et al. Phase-II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. Onkologie 2003; 26: 13-46
62. Mohammed TA, Dennie T, Holen KD. Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study. Clin Adv Hematol Oncol 2011; 9(6): 492-500
63. Kavuri SM, Jain N, Galimi F et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015; 5(8): 832-841
64. Martinelli E, Troiani T, Sforza V et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wildtype, metastatic colorectal cancer: learning from a clinical case. ESMO Open 2018; 3(1): e000299
65. Haslem DS, Ji HP, Ford JM, Nadauld LD. Precision oncology strategy in trastuzumab-resistant human epidermal growth factor receptor 2-positive colon cancer: case report of durable response to ado-trastuxumab emtansine. JCO Precis Oncol 2017; 10.1200/PO.16.00055
66. Parikh A, Atreya C, Korn WM, Venook AP. Prolonged response to HER2-directed therapy in a patient with HER2-amplified, rapidly progressive metastatic colorectal cancer. J Natl Compr Canc Netw 2017; 15(1): 3-8
67. Hyman DM, Piha-Paul SA, Won H et al. HER kinase inhibition in patients with HER2-and HER3-mutant cancers. Nature 2018; 554(7691): 189-194
68. Sartore-Bianchi A, Marsoni S, Siena S. Human epidermal growth factor receptor 2 as a molecular biomarker for metastatic colorectal cancer. JAMA Oncol 2018; 4(1): 19-20
69. André F. Developing anticancer drugs in orphan molecular entities-a paradigm under construction. N Engl J Med 2018; 378(8): 763-765
70. Peeters M, Oliner KS, Price TJ et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 2015; 21(24): 5469-5479
71. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371(17): 1609-1618
72. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369(11): 1023-1034
73. Gelsomino F, Barbolini M, Spallanzani A et al. The evolving role of microsatellite instability in colorectal cancer: a review. Cancer Treat Rev 2016; 51: 19-26
74. Corcoran RB, André T, Atreya CE et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 2018; 8(4): 428-443
75. Overman MJ, McDermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an openlabel, multicentre, phase 2 study. Lancet Oncol 2017; 18(9): 1182-1191